{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:09:27Z","timestamp":1762430967334},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ejca.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T23:50:06Z","timestamp":1426117806000},"page":"825-832","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients"],"prefix":"10.1016","volume":"51","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edibe","family":"Erol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Pujade","family":"Lauraine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2015.01.008_b0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2004.04.025","article-title":"The impact of treatment for genital cancer on quality of life and body image\u2013results of a prospective longitudinal 10-year study","volume":"94","author":"Hawighorst-Knapstein","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.01.008_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","article-title":"Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women\u2019s cancers. Results of a prospective study","volume":"16","author":"Hackbarth","year":"2008","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2015.01.008_b0015","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00520-011-1338-y","article-title":"Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf","volume":"20","author":"Erol","year":"2012","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.01.008_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.10630","article-title":"Changing patient perceptions of the side effects of cancer chemotherapy","volume":"95","author":"Carelle","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.01.008_b0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejon.2012.06.003","article-title":"A comparison of men and women\u2019s experiences of chemotherapy-induced alopecia","volume":"17","author":"Can","year":"2013","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.ejca.2015.01.008_b0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01262572","article-title":"Changes in self-concept and body image during alopecia induced cancer chemotherapy","volume":"5","author":"M\u00fcnstedt","year":"1997","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2015.01.008_b0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00002820-199408000-00006","article-title":"Social and cultural dimensions of hair loss in women treated for breast cancer","volume":"17","author":"Freedman","year":"1994","journal-title":"Cancer Nurs"},{"issue":"2","key":"10.1016\/j.ejca.2015.01.008_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1471-6712.1992.tb00128.x","article-title":"Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer","volume":"6","author":"Tierney","year":"1992","journal-title":"Scand J Caring Sci"},{"key":"10.1016\/j.ejca.2015.01.008_b0045","first-page":"83","article-title":"Alopecia and chemotherapy","volume":"35","author":"Welch","year":"1980","journal-title":"Am J Nurs"},{"issue":"3","key":"10.1016\/j.ejca.2015.01.008_b0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.ftd.0000158867.66994.91","article-title":"Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma","volume":"27","author":"Elis","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"17","key":"10.1016\/j.ejca.2015.01.008_b0055","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2015.01.008_b0060","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2015.01.008_b0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"10.1016\/j.ejca.2015.01.008_b0070","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.01.008_b0075","first-page":"263","article-title":"International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary","volume":"156","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejca.2015.01.008_b0080","series-title":"Cancer: principles and practice of oncology","first-page":"536","article-title":"Cancer of the lung","author":"Minna","year":"1984"},{"key":"10.1016\/j.ejca.2015.01.008_b0085","unstructured":"National Cancer Institute. cancer therapy evaluation program: common toxicity criteria. Available from: http:\/\/ctep.cancer.gov\/reporting\/ctc.html [publish Date: August 9, 2006]."},{"issue":"5","key":"10.1016\/j.ejca.2015.01.008_b0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/mehy.1998.0790","article-title":"Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin\u2019s disease","volume":"53","author":"Lishner","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ejca.2015.01.008_b0095","first-page":"1","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicentre, open-label, phase 3 trial","volume":"1","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2015.01.008_b0100","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.ejca.2014.08.017","article-title":"Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?","volume":"50","author":"Soveri","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.01.008_b0105","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1002\/cncr.28072","article-title":"Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer","volume":"119","author":"Innominato","year":"2013","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:55:22Z","timestamp":1537797322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0959804915000398"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.01.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}